Loading…
Adherence to Hepatitis C Virus Therapy and Early Virologic Outcomes
Background.Suboptimal drug exposure attributable to physician-directed dosage reductions of pegylated interferon and/or ribavirin are associated with decreased sustained virologic response rates. However, data are limited with regard to suboptimal drug exposure that is attributable to missed doses b...
Saved in:
| Published in: | Clinical infectious diseases 2009-01, Vol.48 (2), p.186-193 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c538t-75f72785d7a7421dfde9ece9b4981ea6eae290b041fe3199fe670b92bdc84f953 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c538t-75f72785d7a7421dfde9ece9b4981ea6eae290b041fe3199fe670b92bdc84f953 |
| container_end_page | 193 |
| container_issue | 2 |
| container_start_page | 186 |
| container_title | Clinical infectious diseases |
| container_volume | 48 |
| creator | Lo Re, Vincent Amorosa, Valerianna K. Localio, A. Russell O'Flynn, Rose Teal, Valerie Stein, Zachariah Dorey Kostman, Jay R. Gross, Robert |
| description | Background.Suboptimal drug exposure attributable to physician-directed dosage reductions of pegylated interferon and/or ribavirin are associated with decreased sustained virologic response rates. However, data are limited with regard to suboptimal drug exposure that is attributable to missed doses by patients with chronic hepatitis C virus (HCV) infection. We examined the relationship between adherence to pegylated interferon and ribavirin therapy, measured by pharmacy refill, and HCV suppression during the initial 12 weeks of therapy. Methods.We conducted a cohort study involving 188 patients with chronic HCV infection who were treated with pegylated interferon plus ribavirin. Adherence was calculated using pharmacy refill data and could exceed 100%. The primary outcome was decrease in HCV load at 12 weeks; early virologic response was a secondary outcome. Mixed-effects regression models estimated the association between adherence and HCV suppression during the initial 12 weeks. Subanalyses were performed among patients who received optimal weight-based dosages. Results.The mean decrease in HCV load at 12 weeks was 0.66 log IU/mL greater for patients with ⩾85% adherence than for those with |
| doi_str_mv | 10.1086/595685 |
| format | article |
| fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2668718</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>40309336</jstor_id><oup_id>10.1086/595685</oup_id><sourcerecordid>40309336</sourcerecordid><originalsourceid>FETCH-LOGICAL-c538t-75f72785d7a7421dfde9ece9b4981ea6eae290b041fe3199fe670b92bdc84f953</originalsourceid><addsrcrecordid>eNp1kV9rFDEUxQdRbK36DZRR0LfRZPL_RWiX6hYW24cqxZeQydxps85OpklG3G9vyizbKvgQbsj53XNvOEXxEqMPGEn-kSnGJXtUHGJGRMWZwo_zHTFZUUnkQfEsxjVCGEvEnhYHWOWefA6LxXF7AwEGC2Xy5RJGk1xysVyU312YYnmZVTNuSzO05akJ_fbu3ff-2tnyfErWbyA-L550po_wYlePim-fTy8Xy2p1_uVscbyqLCMyVYJ1ohaStcIIWuO2a0GBBdVQJTEYDgZqhRpEcQcEK9UBF6hRddNaSTvFyFHxafYdp2YDrYUhBdPrMbiNCVvtjdN_K4O70df-l645lwLLbPB-ZxD87QQx6Y2LFvreDOCnqGtMCaGCZPDtP-DaT2HIn8uMUrxGVN272eBjDNDtN8FI34Wi51Ay-Prh3vfYLoUMvNsBJlrTd8EM1sU9V2NElFQ0c29mzk_j_4e9mpl1TD7sKYoIUoTwrFez7mKC33vdhJ-aCyKYXl790Bfk6-pqdXGiOfkDEcC2Ow</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219962049</pqid></control><display><type>article</type><title>Adherence to Hepatitis C Virus Therapy and Early Virologic Outcomes</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>JSTOR Archival Journals and Primary Sources Collection</source><creator>Lo Re, Vincent ; Amorosa, Valerianna K. ; Localio, A. Russell ; O'Flynn, Rose ; Teal, Valerie ; Stein, Zachariah Dorey ; Kostman, Jay R. ; Gross, Robert</creator><creatorcontrib>Lo Re, Vincent ; Amorosa, Valerianna K. ; Localio, A. Russell ; O'Flynn, Rose ; Teal, Valerie ; Stein, Zachariah Dorey ; Kostman, Jay R. ; Gross, Robert</creatorcontrib><description>Background.Suboptimal drug exposure attributable to physician-directed dosage reductions of pegylated interferon and/or ribavirin are associated with decreased sustained virologic response rates. However, data are limited with regard to suboptimal drug exposure that is attributable to missed doses by patients with chronic hepatitis C virus (HCV) infection. We examined the relationship between adherence to pegylated interferon and ribavirin therapy, measured by pharmacy refill, and HCV suppression during the initial 12 weeks of therapy. Methods.We conducted a cohort study involving 188 patients with chronic HCV infection who were treated with pegylated interferon plus ribavirin. Adherence was calculated using pharmacy refill data and could exceed 100%. The primary outcome was decrease in HCV load at 12 weeks; early virologic response was a secondary outcome. Mixed-effects regression models estimated the association between adherence and HCV suppression during the initial 12 weeks. Subanalyses were performed among patients who received optimal weight-based dosages. Results.The mean decrease in HCV load at 12 weeks was 0.66 log IU/mL greater for patients with ⩾85% adherence than for those with <85% adherence (3.23 vs. 2.57 log IU/mL; P=.04). When patients who received a suboptimal ribavirin dosage were excluded, the decrease in viral load was 1.00 log IU/mL greater for persons with ⩾85% adherence (3.32 vs. 2.32 log IU/mL; P=.01). Early virologic response was more common among patients with ⩾85% adherence than it was among those with <85% adherence to treatment with pegylated interferon (73% vs. 29%; P=.02) and ribavirin (73% vs. 55%; P=.08). Conclusions.Adherence of ⩾85% to pegylated interferon and ribavirin treatment was associated with increased HCV suppression. Decreases in HCV load became greater when patients with ⩾85% adherence to their regimen continued to receive their recommended weight-based ribavirin dosage.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/595685</identifier><identifier>PMID: 19086908</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Oxford: The University of Chicago Press</publisher><subject>Antiviral Agents - therapeutic use ; Articles and Commentaries ; Biological and medical sciences ; Chronic hepatitis ; Clinical outcomes ; Cohort Studies ; Dosage ; Drug prescriptions ; Drug therapy ; Female ; Genotypes ; Health outcomes ; Hepatitis ; Hepatitis C ; Hepatitis C virus ; Hepatitis C, Chronic - drug therapy ; Human viral diseases ; Humans ; Infections ; Infectious diseases ; Interferon alpha-2 ; Interferon-alpha - therapeutic use ; Male ; Medical sciences ; Medication Adherence ; Medications ; Middle Aged ; Pharmacies ; Polyethylene Glycols ; Proteins ; Recombinant Proteins ; Regression Analysis ; Ribavirin - therapeutic use ; Time Factors ; Treatment Outcome ; Viral diseases ; Viral hepatitis ; Viral Load ; Virology</subject><ispartof>Clinical infectious diseases, 2009-01, Vol.48 (2), p.186-193</ispartof><rights>Copyright 2008 Infectious Diseases Society of America</rights><rights>2009 by the Infectious Diseases Society of America 2009</rights><rights>2009 INIST-CNRS</rights><rights>Copyright University of Chicago, acting through its Press Jan 15, 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c538t-75f72785d7a7421dfde9ece9b4981ea6eae290b041fe3199fe670b92bdc84f953</citedby><cites>FETCH-LOGICAL-c538t-75f72785d7a7421dfde9ece9b4981ea6eae290b041fe3199fe670b92bdc84f953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/40309336$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/40309336$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,315,786,790,891,27957,27958,58593,58826</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21039894$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19086908$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lo Re, Vincent</creatorcontrib><creatorcontrib>Amorosa, Valerianna K.</creatorcontrib><creatorcontrib>Localio, A. Russell</creatorcontrib><creatorcontrib>O'Flynn, Rose</creatorcontrib><creatorcontrib>Teal, Valerie</creatorcontrib><creatorcontrib>Stein, Zachariah Dorey</creatorcontrib><creatorcontrib>Kostman, Jay R.</creatorcontrib><creatorcontrib>Gross, Robert</creatorcontrib><title>Adherence to Hepatitis C Virus Therapy and Early Virologic Outcomes</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><addtitle>Clinical Infectious Diseases</addtitle><description>Background.Suboptimal drug exposure attributable to physician-directed dosage reductions of pegylated interferon and/or ribavirin are associated with decreased sustained virologic response rates. However, data are limited with regard to suboptimal drug exposure that is attributable to missed doses by patients with chronic hepatitis C virus (HCV) infection. We examined the relationship between adherence to pegylated interferon and ribavirin therapy, measured by pharmacy refill, and HCV suppression during the initial 12 weeks of therapy. Methods.We conducted a cohort study involving 188 patients with chronic HCV infection who were treated with pegylated interferon plus ribavirin. Adherence was calculated using pharmacy refill data and could exceed 100%. The primary outcome was decrease in HCV load at 12 weeks; early virologic response was a secondary outcome. Mixed-effects regression models estimated the association between adherence and HCV suppression during the initial 12 weeks. Subanalyses were performed among patients who received optimal weight-based dosages. Results.The mean decrease in HCV load at 12 weeks was 0.66 log IU/mL greater for patients with ⩾85% adherence than for those with <85% adherence (3.23 vs. 2.57 log IU/mL; P=.04). When patients who received a suboptimal ribavirin dosage were excluded, the decrease in viral load was 1.00 log IU/mL greater for persons with ⩾85% adherence (3.32 vs. 2.32 log IU/mL; P=.01). Early virologic response was more common among patients with ⩾85% adherence than it was among those with <85% adherence to treatment with pegylated interferon (73% vs. 29%; P=.02) and ribavirin (73% vs. 55%; P=.08). Conclusions.Adherence of ⩾85% to pegylated interferon and ribavirin treatment was associated with increased HCV suppression. Decreases in HCV load became greater when patients with ⩾85% adherence to their regimen continued to receive their recommended weight-based ribavirin dosage.</description><subject>Antiviral Agents - therapeutic use</subject><subject>Articles and Commentaries</subject><subject>Biological and medical sciences</subject><subject>Chronic hepatitis</subject><subject>Clinical outcomes</subject><subject>Cohort Studies</subject><subject>Dosage</subject><subject>Drug prescriptions</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Genotypes</subject><subject>Health outcomes</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Interferon alpha-2</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medication Adherence</subject><subject>Medications</subject><subject>Middle Aged</subject><subject>Pharmacies</subject><subject>Polyethylene Glycols</subject><subject>Proteins</subject><subject>Recombinant Proteins</subject><subject>Regression Analysis</subject><subject>Ribavirin - therapeutic use</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><subject>Viral Load</subject><subject>Virology</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNp1kV9rFDEUxQdRbK36DZRR0LfRZPL_RWiX6hYW24cqxZeQydxps85OpklG3G9vyizbKvgQbsj53XNvOEXxEqMPGEn-kSnGJXtUHGJGRMWZwo_zHTFZUUnkQfEsxjVCGEvEnhYHWOWefA6LxXF7AwEGC2Xy5RJGk1xysVyU312YYnmZVTNuSzO05akJ_fbu3ff-2tnyfErWbyA-L550po_wYlePim-fTy8Xy2p1_uVscbyqLCMyVYJ1ohaStcIIWuO2a0GBBdVQJTEYDgZqhRpEcQcEK9UBF6hRddNaSTvFyFHxafYdp2YDrYUhBdPrMbiNCVvtjdN_K4O70df-l645lwLLbPB-ZxD87QQx6Y2LFvreDOCnqGtMCaGCZPDtP-DaT2HIn8uMUrxGVN272eBjDNDtN8FI34Wi51Ay-Prh3vfYLoUMvNsBJlrTd8EM1sU9V2NElFQ0c29mzk_j_4e9mpl1TD7sKYoIUoTwrFez7mKC33vdhJ-aCyKYXl790Bfk6-pqdXGiOfkDEcC2Ow</recordid><startdate>20090115</startdate><enddate>20090115</enddate><creator>Lo Re, Vincent</creator><creator>Amorosa, Valerianna K.</creator><creator>Localio, A. Russell</creator><creator>O'Flynn, Rose</creator><creator>Teal, Valerie</creator><creator>Stein, Zachariah Dorey</creator><creator>Kostman, Jay R.</creator><creator>Gross, Robert</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20090115</creationdate><title>Adherence to Hepatitis C Virus Therapy and Early Virologic Outcomes</title><author>Lo Re, Vincent ; Amorosa, Valerianna K. ; Localio, A. Russell ; O'Flynn, Rose ; Teal, Valerie ; Stein, Zachariah Dorey ; Kostman, Jay R. ; Gross, Robert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c538t-75f72785d7a7421dfde9ece9b4981ea6eae290b041fe3199fe670b92bdc84f953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>Articles and Commentaries</topic><topic>Biological and medical sciences</topic><topic>Chronic hepatitis</topic><topic>Clinical outcomes</topic><topic>Cohort Studies</topic><topic>Dosage</topic><topic>Drug prescriptions</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Genotypes</topic><topic>Health outcomes</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Interferon alpha-2</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medication Adherence</topic><topic>Medications</topic><topic>Middle Aged</topic><topic>Pharmacies</topic><topic>Polyethylene Glycols</topic><topic>Proteins</topic><topic>Recombinant Proteins</topic><topic>Regression Analysis</topic><topic>Ribavirin - therapeutic use</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><topic>Viral Load</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lo Re, Vincent</creatorcontrib><creatorcontrib>Amorosa, Valerianna K.</creatorcontrib><creatorcontrib>Localio, A. Russell</creatorcontrib><creatorcontrib>O'Flynn, Rose</creatorcontrib><creatorcontrib>Teal, Valerie</creatorcontrib><creatorcontrib>Stein, Zachariah Dorey</creatorcontrib><creatorcontrib>Kostman, Jay R.</creatorcontrib><creatorcontrib>Gross, Robert</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lo Re, Vincent</au><au>Amorosa, Valerianna K.</au><au>Localio, A. Russell</au><au>O'Flynn, Rose</au><au>Teal, Valerie</au><au>Stein, Zachariah Dorey</au><au>Kostman, Jay R.</au><au>Gross, Robert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adherence to Hepatitis C Virus Therapy and Early Virologic Outcomes</atitle><jtitle>Clinical infectious diseases</jtitle><stitle>Clinical Infectious Diseases</stitle><addtitle>Clinical Infectious Diseases</addtitle><date>2009-01-15</date><risdate>2009</risdate><volume>48</volume><issue>2</issue><spage>186</spage><epage>193</epage><pages>186-193</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><notes>istex:B055CDA2113EEA1B253BFD7B88ACF4E2DB127206</notes><notes>ark:/67375/HXZ-P3NLXLPB-6</notes><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-1</notes><notes>content type line 23</notes><abstract>Background.Suboptimal drug exposure attributable to physician-directed dosage reductions of pegylated interferon and/or ribavirin are associated with decreased sustained virologic response rates. However, data are limited with regard to suboptimal drug exposure that is attributable to missed doses by patients with chronic hepatitis C virus (HCV) infection. We examined the relationship between adherence to pegylated interferon and ribavirin therapy, measured by pharmacy refill, and HCV suppression during the initial 12 weeks of therapy. Methods.We conducted a cohort study involving 188 patients with chronic HCV infection who were treated with pegylated interferon plus ribavirin. Adherence was calculated using pharmacy refill data and could exceed 100%. The primary outcome was decrease in HCV load at 12 weeks; early virologic response was a secondary outcome. Mixed-effects regression models estimated the association between adherence and HCV suppression during the initial 12 weeks. Subanalyses were performed among patients who received optimal weight-based dosages. Results.The mean decrease in HCV load at 12 weeks was 0.66 log IU/mL greater for patients with ⩾85% adherence than for those with <85% adherence (3.23 vs. 2.57 log IU/mL; P=.04). When patients who received a suboptimal ribavirin dosage were excluded, the decrease in viral load was 1.00 log IU/mL greater for persons with ⩾85% adherence (3.32 vs. 2.32 log IU/mL; P=.01). Early virologic response was more common among patients with ⩾85% adherence than it was among those with <85% adherence to treatment with pegylated interferon (73% vs. 29%; P=.02) and ribavirin (73% vs. 55%; P=.08). Conclusions.Adherence of ⩾85% to pegylated interferon and ribavirin treatment was associated with increased HCV suppression. Decreases in HCV load became greater when patients with ⩾85% adherence to their regimen continued to receive their recommended weight-based ribavirin dosage.</abstract><cop>Oxford</cop><pub>The University of Chicago Press</pub><pmid>19086908</pmid><doi>10.1086/595685</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2009-01, Vol.48 (2), p.186-193 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2668718 |
| source | Oxford University Press Journals All Titles (1996-Current); JSTOR Archival Journals and Primary Sources Collection |
| subjects | Antiviral Agents - therapeutic use Articles and Commentaries Biological and medical sciences Chronic hepatitis Clinical outcomes Cohort Studies Dosage Drug prescriptions Drug therapy Female Genotypes Health outcomes Hepatitis Hepatitis C Hepatitis C virus Hepatitis C, Chronic - drug therapy Human viral diseases Humans Infections Infectious diseases Interferon alpha-2 Interferon-alpha - therapeutic use Male Medical sciences Medication Adherence Medications Middle Aged Pharmacies Polyethylene Glycols Proteins Recombinant Proteins Regression Analysis Ribavirin - therapeutic use Time Factors Treatment Outcome Viral diseases Viral hepatitis Viral Load Virology |
| title | Adherence to Hepatitis C Virus Therapy and Early Virologic Outcomes |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T14%3A02%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adherence%20to%20Hepatitis%20C%20Virus%20Therapy%20and%20Early%20Virologic%20Outcomes&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Lo%20Re,%20Vincent&rft.date=2009-01-15&rft.volume=48&rft.issue=2&rft.spage=186&rft.epage=193&rft.pages=186-193&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1086/595685&rft_dat=%3Cjstor_pubme%3E40309336%3C/jstor_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c538t-75f72785d7a7421dfde9ece9b4981ea6eae290b041fe3199fe670b92bdc84f953%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=219962049&rft_id=info:pmid/19086908&rft_jstor_id=40309336&rft_oup_id=10.1086/595685&rfr_iscdi=true |